Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001213900-25-096128
Filing Date
2025-10-03
Accepted
2025-10-03 16:30:36
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 19945
2 JOINT FILING STATEMENT ea026016801ex99-1_sab.htm EX-99.1 5338
  Complete submission text file 0001213900-25-096128.txt   27074
Mailing Address 777 W 41ST ST SUITE 401 MIAMI BEACH FL 33140
Business Address 777 W 41ST ST SUITE 401 MIAMI BEACH FL 33140 305-845-2813
SAB Biotherapeutics, Inc. (Subject) CIK: 0001833214 (see all company filings)

EIN.: 853899721 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-92283 | Film No.: 251374388
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 192 LYTTON AVENUE PALO ALTO CA 94301
Business Address 192 LYTTON AVENUE PALO ALTO CA 94301 6506880818
Vivo Opportunity Fund Holdings, L.P. (Filed by) CIK: 0001930214 (see all company filings)

EIN.: 873802421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G